Pō a AoHealing Sanctuary · Knowledge Library
All pages

Veterans · Evidence · Potential outcomes

Hope deserves
the whole truth.

A careful look at the positive outcomes researchers have reported for ibogaine, ketamine and MDMA-assisted therapy—along with who was studied, how strong the evidence is, and what it does not prove.

Educational boundary. This page describes research, not a treatment recommendation. A symptom score is not a cure, a lower suicidal-ideation score is not suicide prevention, and an observational change does not prove that a medicine caused it. In a U.S. crisis, call 988 and press 1 for the Veterans Crisis Line; call 911 for immediate danger.
How to read this page

Potential does not mean promised.

Every card names the outcome, what was studied, the population, evidence strength and limits. Veteran-specific evidence is clearly separated from findings in general adult populations. Regulatory status and safety remain visible even when a result is hopeful.

01

Ibogaine

Schedule I · Not FDA-approved · Investigational

Small studies have reported changes in withdrawal, substance-use severity and, in one narrow veteran cohort, PTSD, depression and disability/functioning scores. These findings are preliminary and do not establish that ibogaine caused the changes.

Potential outcome studied

Lower PTSD, depression and disability/functioning scores after a combined protocol

What was studied
A prospective open-label magnesium–ibogaine protocol with complementary care, group activities and coaching.
In whom
30 male U.S. Special Operations Forces veterans, predominantly with mild traumatic brain injury; 23 had PTSD and 15 had major depressive disorder at baseline.
Evidence strength
Very low certainty for causal efficacy. Veteran-specific, but observational—not randomized or controlled.
Limits
Ibogaine was not studied alone. Self-selection, travel, expectancy and concurrent support could explain some or all change. Follow-up was one month and does not prove durable benefit, cognitive recovery or brain repair.
Open source · Nature Medicine veteran observational study
Potential outcome studied

Lower acute opioid-withdrawal scores

What was studied
Self-reported withdrawal symptoms before and immediately after one legal ibogaine treatment.
In whom
14 adults with opioid dependence in New Zealand; not a veteran-specific study.
Evidence strength
Very low certainty. Small, uncontrolled observational evidence.
Limits
No placebo or usual-care comparison; withdrawal was self-reported; one death occurred during treatment. The result does not establish a safe or proven withdrawal treatment.
Open source · Addiction observational safety study
Potential outcome studied

Lower reported drug-use severity during follow-up

What was studied
Self-reported drug-use severity and use patterns across 12 months.
In whom
The same 14-person New Zealand cohort; only eight completed every interview. Not veteran-specific.
Evidence strength
Very low certainty for sustained addiction outcomes.
Limits
Attrition, selection, self-report and concurrent care prevent conclusions about abstinence, relapse prevention or superiority to established opioid-use-disorder care.
Open source · Twelve-month observational follow-up
What to keep in view

Ibogaine has serious cardiac and neurologic safety signals, including marked QT prolongation, torsades de pointes, cardiac arrest, severe temporary loss of coordination, seizures and deaths. It is not a standard regulated U.S. treatment.

02

Ketamine and esketamine

Racemic ketamine: approved anesthetic; psychiatric use off-label · Esketamine: distinct FDA-approved REMS product

Racemic ketamine and esketamine are related but distinct products. Evidence for a specified product, route and supervised setting should not be transferred to a retreat, home program, compounded product or another formulation.

Potential outcome studied

Rapid, short-term reduction in depressive-symptom severity

What was studied
Medically administered racemic ketamine across randomized controlled trials, commonly intravenous.
In whom
Adults with major depressive episodes, including treatment-resistant depression; mainly general adult populations rather than veteran-only cohorts.
Evidence strength
Moderate for rapid, short-term symptom reduction.
Limits
Studies varied substantially. Effects often peak near one day and tend back toward baseline. Long-term maintenance, functioning, cognition and safety remain less certain; this does not validate retreat or home use.
Open source · 2023 systematic review and meta-analysis
Potential outcome studied

Improved depressive symptoms in specific FDA-labeled esketamine populations

What was studied
Intranasal SPRAVATO under its approved labeling and supervised-use conditions.
In whom
Adults with treatment-resistant depression and specified adults with major depressive disorder and acute suicidal ideation or behavior.
Evidence strength
Strongest regulatory support among the options on this page—but only for the named product, populations and setting.
Limits
The label states that suicide prevention and reduction of suicidal ideation or behavior have not been demonstrated. Esketamine and racemic ketamine are not interchangeable.
Open source · FDA SPRAVATO prescribing information
Potential outcome studied

Rapid reduction in suicidal thoughts as a symptom measure

What was studied
Adjunctive intravenous racemic ketamine versus midazolam, with suicidal-ideation score change measured at 24 hours.
In whom
80 adults with major depressive disorder and clinically significant suicidal ideation; not veteran-specific.
Evidence strength
Limited to moderate for a short-term ideation outcome.
Limits
The study did not show suicide prevention. Lower ideation scores do not prove that a person is safe from self-harm or does not need urgent assessment or hospitalization.
Open source · Randomized controlled trial
Potential outcome studied

Lower depressive symptoms occurring alongside PTSD

What was studied
Repeated intravenous racemic ketamine versus placebo in a multisite double-blind randomized trial.
In whom
158 veterans and active-duty service members with antidepressant-resistant PTSD.
Evidence strength
Low for this population and outcome because it was a secondary result from one trial.
Limits
The same trial found no significant benefit for core PTSD symptoms and did not establish functional improvement. VA/DoD guidance suggests against ketamine for PTSD.
Open source · Veteran and service-member randomized trial
What to keep in view

Supervised ketamine and esketamine carry risks involving blood pressure, sedation, dissociation, respiratory depression, impairment, abuse and misuse. FDA warns that compounded ketamine products do not have the same evaluated quality, safety or effectiveness as an approved product.

03

MDMA-assisted therapy

Schedule I · Not FDA-approved · Investigational

The research concerns pharmaceutical-grade MDMA inside a structured package of screening, preparation, monitored medication sessions and integration psychotherapy—not MDMA alone or an informal setting.

Potential outcome studied

Lower PTSD-symptom severity within a structured therapy protocol

What was studied
Two phase 3 trials compared MDMA plus manualized psychotherapy with placebo plus the same therapy.
In whom
Adults with chronic severe or moderate-to-severe PTSD, chiefly civilian/community samples. One trial included 16 veterans but did not report a veteran-only efficacy analysis.
Evidence strength
Promising replicated short-term randomized-trial signal for the full treatment package; not established clinical effectiveness.
Limits
Small studies, likely functional unblinding, short follow-up and no comparison with a first-line trauma-focused therapy. FDA concluded that the application did not establish substantial evidence of effectiveness and requested further study.
Open source · MAPP1 phase 3 trial
Potential outcome studied

Lower PTSD-related functional-impairment scores

What was studied
Prespecified Sheehan Disability Scale outcomes in the two phase 3 therapy-package trials.
In whom
The mixed adult PTSD trial populations; not a veteran-specific result.
Evidence strength
Moderate short-term randomized evidence for improvement on this measure within the studied protocol.
Limits
The effect was smaller than the symptom result, follow-up was short and the separate contribution of the psychotherapy and medicine cannot be determined.
Open source · MAPP2 phase 3 trial
Potential outcome studied

Lower depressive symptoms occurring alongside PTSD

What was studied
An exploratory analysis of depression scores in the first phase 3 PTSD trial.
In whom
Adults with severe PTSD, many with co-occurring major depression; not designed to test primary depression treatment.
Evidence strength
Exploratory only.
Limits
This does not establish MDMA-assisted therapy as a treatment for depression and carries the same blinding, selection, short-follow-up and regulatory concerns as the parent trial.
Open source · MAPP1 exploratory outcome
What to keep in view

Published pivotal evidence is not veteran-specific. A VA trial in veterans with PTSD and alcohol use disorder began in 2026 but has no posted results. Controlled-trial findings do not establish the safety or effectiveness of nonmedical MDMA or an unregulated program.

What none of this proves

No cure. No guarantee.
No shortcut around care.

The evidence does not prove that any medicine or protocol will help a particular veteran, prevent suicide, repair traumatic brain injury, restore every area of functioning or replace established care. Study outcomes do not automatically transfer to retreats, home programs, compounded products or unknown-source material.

Ask the DocBack to VeteransResearch Center
Need Help?